Erosive Esophagitis: Clinical Trials

7 completed, 1 not yet recruiting. 8 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	8	Completed 7, Not yet recruiting 1

Follow Erosive Esophagitis: new trials by email Literature Review of Erosive Esophagitis trials Research Report on Erosive Esophagitis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis Vonoprazan 20 mg, Esomeprazole - Erosive Esophagitis	Phase 4	Not yet recruiting	Universitas Indonesia	216	2024-12-09	2024-12-17
Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Vonoprazan, Lansoprazole - Erosive Esophagitis	Phase 4	Completed	Takeda	208	2016-03-20	2023-12-13
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy Esomeprazole 40 mg - Erosive Esophagitis	Phase 4	Completed	Chang Gung Memorial Hospital	408	2010-06-01	2018-09-04
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study Omeprazole/sodium bicarbonate - Erosive Esophagitis	Phase 4	Completed	Yvonne Romero	91	2008-01-01	2012-09-20
Esomeprazole for Treatment of GERD in Pediatric Patients Esomeprazole (Nexium) - Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis	Phase 4	Completed	AstraZeneca	100	2004-10-01	2010-11-19
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis esomeprazole magnesium (oral medication) - Erosive Esophagitis, Reflux Esophagitis	Phase 4	Completed	AstraZeneca	120	2004-06-01	2009-03-26
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed Esomeprazole, Lansoprazole - Erosive Esophagitis	Phase 4	Completed	AstraZeneca	750	2002-12-01	2009-03-26
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis Esomeprazole, Lansoprazole - Erosive Esophagitis	Phase 4	Completed	AstraZeneca	1000	2002-12-01	2009-03-26

Narrower conditions

Gastroesophageal Reflux (3)  ·  Esophagitis, Peptic (2)  ·  Heartburn (2)  ·  Esophagitis (1)

Broader conditions

Digestive System Diseases (4)  ·  Esophageal Diseases (4)  ·  Gastrointestinal Diseases (4)  ·  Deglutition Disorders (3)  ·  Esophageal Motility Disorders (3)  ·  Gastroenteritis (3)  ·  Duodenal Diseases (2)  ·  Esophagitis (2)  ·  Intestinal Diseases (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Peptic Ulcer (2)  ·  Signs and Symptoms (2)  ·  Signs and Symptoms, Digestive (2)  ·  Stomach Diseases (2)

Interventions

Esomeprazole (6)  ·  Lansoprazole (3)  ·  1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (2)  ·  Dosage Forms (1)  ·  omeprazole, sodium bicarbonate drug combination (1)

Sponsors

AstraZeneca (4)  ·  Chang Gung Memorial Hospital (1)  ·  Takeda (1)  ·  Universitas Indonesia (1)  ·  Yvonne Romero (1)

Countries

United States (3)  ·  Belgium (1)  ·  France (1)  ·  Indonesia (1)  ·  Italy (1)  ·  Japan (1)  ·  Taiwan (1)

Top investigators

Paula Fernstrom (2)  ·  Ari F Syam, MD (1)  ·  Seng-Kee Chuah, M.D (1)  ·  Yvonne Romero, M.D. (1)

Results publications

PMID 17305763, PMID 18493207, PMID 20540767, PMID 20706150, PMID 25245625, PMID 26121347, PMID 26121348, PMID 26422095, PMID 26422096, PMID 39209187